Takada, Junichi
Dinavahi, Rajani
Miyauchi, Akimitsu
Hamaya, Etsuro
Hirama, Toshiyasu
Libanati, Cesar
Nakamura, Yoichi
Milmont, Cassandra E.
Grauer, Andreas
Funding for this research was provided by:
Amgen Inc.,
UCB Pharma
Article History
Received: 16 May 2019
Accepted: 21 October 2019
First Online: 9 November 2019
Change Date: 20 March 2020
Change Type: Correction
Change Details: In the original publication of the article, the last row of Table��1 was published incorrectly as ���Serum P1NP (��mol/L), median (IQR)<sup>b</sup> : Romosozumab, 25 (18, 34); Teriparatide, 25 (20, 33)���. The correct row should be read as ���Serum P1NP (��g/L), median (IQR)<sup>b</sup> : Romosozumab, 25 (18, 34); Teriparatide, 25 (20, 33)���.
Compliance with ethical standards
:
: Rajani Dinavahi, Cassandra E. Milmont, and Andreas Grauer are employees of Amgen Inc., USA, and report holding stocks of Amgen Inc. Etsuro Hamaya, Toshiyasu Hirama, and Yoichi Nakamura are employees of Amgen Astellas BioPharma K.K., Japan. Additionally, Etsuro Hamaya and Toshiyasu Hirama report holding stocks of Amgen Inc. Cesar Libanati is an employee of UCB Pharma, Belgium, and reports holding stocks of UCB Pharma. Junichi Takada and Akimitsu Miyauchi have nothing to disclose.
: This study was done in accordance with International Conference on Harmonization Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. An independent ethics committee or institutional review board at each site approved the protocol, informed consent form, and all protocol amendments.
: Patients gave written informed consent before any study-specific procedures were done.